FINANCIAL REPORTING
Operating Sheets & Quarterly Results
Official performance reports, production metrics, and quarterly operating sheets of Marigold Pharmaceuticals (P) Ltd..
Q4 REPORT
Q4 FY2025-26 Performance
Capacity utilization reached 92% across Solapur cGMP formulation units with a 24% growth in CDMO international contracts.
Q3 REPORT
Q3 FY2025-26 Performance
Commercialization of 6 new peptide generic formulations and expansion of cleanroom packaging line.
ANNUAL SUMMARY
Annual Operational Highlights
Consistent compliance track record with zero 483 critical observations and successful expansion into global semi-regulated markets.
Recent Disclosures & Filings
| Document Name | Period | Status | Access |
|---|---|---|---|
| Annual Financial Statement 2025-26 | Full Year | Audited | Request Copy — |
| Operational Review & Production Metrics | Q3 2025-26 | Published | Request Copy — |
| Quality & Compliance Annual Report | 2025-26 | Certified | Request Copy — |